The effectiveness of Omalizumab in the treatment of Hyper-IgE syndrome: A case report

Authors

  • raneem nsour Jordan University of Science and Technology
  • aseel alkhatib Faculty of medicine, Jordan University of Science and Technology
  • rama shannak Faculty of medicine, Jordan University of Science and Technology
  • ammar daoud Department of Internal Medicine, Faculty of Medicine, Jordan University of Science and Technology

DOI:

https://doi.org/10.58877/japaj.v1i3.61

Keywords:

Job's syndrome, HIES, Omalizumab, IVIG

Abstract

BACKGROUND - Hyper-immunoglobulin E (IgE) syndrome (HIES) is a rare primary multisystem immunodeficiency disorder with an incidence of one case per million population. It is characterized by elevated serum IgE levels, dermatitis, recurrent skin and lung infections, skeletal abnormalities such as scoliosis, and distinctive facial features. Moreover, the clinical manifestations may include vascular, dental, joint, and brain abnormalities. Treatment for HIES predominantly targets symptom relief. Omalizumab, a monoclonal antibody, works by inhibiting the binding of free IgE to receptors on effector cells, consequently reducing the release of inflammatory mediators and alleviating some cutaneous and respiratory symptoms of HIES. To date, according to our understanding, no treatment protocol for HIES patients exists in Jordan. To fill this gap, we report our experience using omalizumab and intravenous immunoglobulin (IVIG) in treating the first documented case of HIES in Jordan.  CASE PRESENTATION - We present the case of an 18-year-old male patient who had been diagnosed with HIES since infancy. The patient had been subjected to multiple treatment trials, but none proved effective. In our treatment protocol, 150 mg of omalizumab was administered subcutaneously every 2 weeks, later increasing to 300 mg. Following this treatment, the eczema symptoms and eosinophil count showed a marked reduction. The patient’s IgE level decreased from 21,800 IU/ml in 2011 and 2,039 IU/ml in 2019 to 764 IU/ml in 2022, with treatment commencing in the latter year.   CONCLUSION - The combined use of omalizumab and IVIG therapies demonstrated efficacy in reducing the elevated IgE levels and symptom severity in our patient. There is a need for more case studies to report clinical findings in the management of HIES

References

Alonso-Bello CD, Jiménez-Martínez M del C, Vargas-Camaño ME, Hierro-Orozco S, Ynga-Durand MA, Berrón-Ruiz L, et al. Partial and Transient Clinical Response to Omalizumab in IL-21-Induced Low STAT3-Phosphorylation on Hyper-IgE Syndrome. Case Reports Immunol. 2019 Jul 4;2019:1–5. DOI: https://doi.org/10.1155/2019/6357256

Sowerwine KJ, Holland SM, Freeman AF. Hyper-IgE syndrome update. Ann N Y Acad Sci. 2012;1250(1):25–32. DOI: https://doi.org/10.1111/j.1749-6632.2011.06387.x

Chia JC, Mydlarski PR. Dermatologic uses of omalizumabtitle*. Vol. 28, Journal of Dermatological Treatment. Taylor and Francis Ltd; 2017. p. 332–7. DOI: https://doi.org/10.1080/09546634.2016.1249819

Lan J, Zhang Y, Song M, Cai S, Luo H, OuYang R, et al. Omalizumab for STAT3 Hyper-IgE Syndromes in Adulthood: A Case Report and Literature Review. Front Med (Lausanne). 2022 May 4;9. DOI: https://doi.org/10.3389/fmed.2022.835257

Gomes N, Miranda J, Lopes S, Carneiro-Leão L, Torres Costa J, Baudrier T, et al. Omalizumab in the treatment of hyper-ige syndrome: 2 case reports. Vol. 30, Journal of Investigational Allergology and Clinical Immunology. ESMON Publicidad S.A.; 2020. p. 191–2. DOI: https://doi.org/10.18176/jiaci.0469

Downloads

Published

2023-10-12

How to Cite

nsour, raneem, alkhatib, aseel, shannak, rama, & daoud, ammar. (2023). The effectiveness of Omalizumab in the treatment of Hyper-IgE syndrome: A case report. JAP Academy Journal, 1(3). https://doi.org/10.58877/japaj.v1i3.61

Issue

Section

Case Reports and Case Series